Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia

Excerpt

Chronic lymphocytic leukemia (CLL) is a complex hematologic malignancy following a highly variable clinical course [1]. Approximately one-third of CLL patients have an indolent disease course, surviving several years without needing therapy, whereas others suffer from aggressive disease and require treatment early in the disease process [1, 2]. The combinations of new novel agents and targeted therapies with conventional chemotherapy have yielded better response rates CLL cases, but these therapies have proven inferior to allogeneic hematopoietic stem cell transplant (allo-HSCT) in terms of achieving long-term disease control and ultimately cure, especially in patients with relapsed/refractory disease [1‐4]. …